Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

作者：Chanan Khan Asher A^*; Kaufman Jonathan L; Mehta Jayesh; Richardson Paul G; Miller Kena C; Lonial Sagar; Munshi Nikhil C; Schlossman Robert; Tariman Joseph; Singhal Seema

来源：Blood, 2007, 109(6): 2604-2606.

DOI：10.1182/blood-2006-09-046409

Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.

• 出版日期2007-3-15
• 单位西北大学